Jianmin Group disclosed the semi -annual report of 2022: Realizing net profit of 198 million yuan

On July 20, 2022, A -share listed company Jianmin Group (code: 600976.SH) released the semi -annual performance report in 2022.

From January 1, 2022-June 30, 2022, the company realized operating income of 1.827 billion yuan, an increase of 1.93%year-on-year, and net profit was 198 million yuan, an increase of 18.70%year-on-year, and the basic earnings per share were 1.31 yuan.

The company's industry is Chinese medicine.

Among them, the revenue of the pharmaceutical production and sales section revenue was 1.677 billion yuan, the income of the commercial branch was 930 billion yuan, and the income between the divisions offset-779 million yuan.

During the company's reporting period, the total assets at the end of the period were 2.929 billion yuan, the operating profit was 220 million yuan, the accounts receivable were 609 million yuan, and the net cash flow generated by operating activities was 83.999 million yuan.Cash is 1772 billion yuan.

Jianmin Group, the company's full name, Jianmin Pharmaceutical Group Co., Ltd., was established on May 28, 1993. It is currently general manager Wang Jun. The main business is the research and development, manufacturing, wholesale and retail business of drugs.

- END -